Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
GI Innovation, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Astellas Pharma Inc
PMV Pharmaceuticals, Inc
Mayo Clinic
Neonc Technologies, Inc.
Merck Sharp & Dohme LLC
Essen Biotech
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Genenta Science
Weill Medical College of Cornell University
University of California, Davis
University of California, Davis
Takeda
University of Iowa
Twinpig Biolab, Inc.
BicycleTx Limited
Astellas Pharma Inc
Dana-Farber Cancer Institute
Dragonfly Therapeutics
BioXcel Therapeutics Inc
Maastricht University Medical Center
Scancell Ltd
Vyriad, Inc.
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
NuCana plc
Aprea Therapeutics
Hoosier Cancer Research Network
University of Colorado, Denver
RAPT Therapeutics, Inc.
Nimbus Therapeutics
GI Innovation, Inc.
Simcha IL-18, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
Sumitomo Pharma America, Inc.
Advaxis, Inc.
GeneMedicine Co., Ltd.
Evopoint Biosciences Inc.
Pharmacyclics LLC.
Peter MacCallum Cancer Centre, Australia
University of Wisconsin, Madison
Peter MacCallum Cancer Centre, Australia
Kineta Inc.